BioComo
BioComo Inc. is a pioneering biotech company engaged in the research and development of vaccines and biopharmaceuticals. Collaborating with Mie University and other partners, it focuses on developing innovative vaccine platforms, including nasal spray vaccines for respiratory viruses such as RSV and COVID-19. The company utilizes advanced vector technologies, including the BC-PIV platform based on human parainfluenza virus type 2, to create safe and effective vaccines for infectious diseases and cancer. With a strong emphasis on cutting-edge research, BioComo aims to contribute to global health by developing next-generation vaccines and immunotherapies.
Industries
Nr. of Employees
small (1-50)
BioComo
Products
hPIV2-based antigen delivery platform
A recombinant viral vector platform derived from human parainfluenza virus type 2 designed to deliver protein/peptide antigens for vaccine and immunotherapy applications, optimized for antigen payload size and reduced replication risk.
hPIV2-based antigen delivery platform
A recombinant viral vector platform derived from human parainfluenza virus type 2 designed to deliver protein/peptide antigens for vaccine and immunotherapy applications, optimized for antigen payload size and reduced replication risk.
Services
Research and development services for recombinant viral vector vaccines, including vector design, antigen incorporation, and preclinical evaluation.
Joint research agreements, technology transfer, and IP licensing related to the hPIV2-derived antigen delivery platform.
Arranging and coordinating manufacturing contracts with external contract manufacturing organizations for vaccine production.
Research and development services for recombinant viral vector vaccines, including vector design, antigen incorporation, and preclinical evaluation.
Joint research agreements, technology transfer, and IP licensing related to the hPIV2-derived antigen delivery platform.
Arranging and coordinating manufacturing contracts with external contract manufacturing organizations for vaccine production.
Expertise Areas
- Viral vector vaccine development
- Intranasal vaccine delivery
- Cancer immunotherapy using vector delivery
- Preclinical efficacy and immunogenicity testing
Key Technologies
- Recombinant viral vector design (hPIV2-based)
- Intranasal/nasal-spray delivery platforms
- Vero-derived production cell lines
- Low-energy electron-mediated viral inactivation (LEEI)
News & Updates
Joint development of a nasal spray vaccine for RSV in Japan, with manufacturing contracted to TFBS Bioscience Inc.
Mie University and BioComo Inc. have entrusted TFBS Bioscience in Taiwan with vaccine manufacturing for the nasal spray RSV vaccine.
Development of a nasal spray COVID-19 vaccine showing significant efficacy in upper and lower respiratory tracts.
Participation and presentation at BIO2019 in Philadelphia.
Introduction of new solid tumor treatment agents at the Japan Healthcare Venture Summit 2018.
Patent related to recombinant vaccine vectors holding antigen proteins, granted in the US.
Joint development of a nasal spray vaccine for RSV in Japan, with manufacturing contracted to TFBS Bioscience Inc.
Mie University and BioComo Inc. have entrusted TFBS Bioscience in Taiwan with vaccine manufacturing for the nasal spray RSV vaccine.
Development of a nasal spray COVID-19 vaccine showing significant efficacy in upper and lower respiratory tracts.
Participation and presentation at BIO2019 in Philadelphia.
Introduction of new solid tumor treatment agents at the Japan Healthcare Venture Summit 2018.
Patent related to recombinant vaccine vectors holding antigen proteins, granted in the US.